Although eosinophilia after stem cell transplantation (SCT) has been addressed in recent reports, the significance of eosinophilia in disease outcome after SCT has not been well studied. In this study, we investigate the frequency of eosinophilia after SCT to determine its prognostic value. The subjects were 113 patients with malignant or nonmalignant diseases who underwent SCT treatment. In these patients, eosinophilia was detected in 44 cases (38.9%), on average 67.5 days after transplantation, and the mean maximum absolute eosinophil count was 840.5 Â 10 6 /l. To study the basis of eosinophilia after SCT, various serum cytokine levels during SCT in patients both with and without eosinophilia were analyzed. Statistical analysis indicated that the overall patient survival rates improved in those with eosinophilia compared to those without eosinophilia (88.7 vs 43.0%, P ¼ 0.0034). In particular, in patients with malignant diseases, those with eosinophilia showed a higher eventfree survival (81.1 vs 44.6%, P ¼ 0.0025) and a lower relapse rate (16.0 vs 43.0%, P ¼ 0.0287) than those without eosinophilia. In conclusion, we propose that eosinophilia after SCT could be a useful prognostic marker for determining favorable outcomes in patients with malignant diseases. The reasons for this good prognosis in SCT patients with eosinophilia are discussed. Bone Marrow Transplantation (2005) 36, 985-991.
Stem cell transplantation (SCT) has improved the survival rate of patients with certain hematological disorders including malignancy, congenital metabolic disorders, and primary immunodeficiencies. [1] [2] [3] [4] Recently, several interesting findings related to the occurrence of eosinophilia after allogeneic SCT have been reported. McNeel et al 5 reported two cases of hypereosinophilia as an early sign of acute graft-versus-host disease (GVHD) after allogeneic SCT. Patients were treated with glucocorticoids, resulting in resolution of both eosinophilia and GVHD symptoms. Daneshpouy et al 6 examined the relationship between eosinophilia and digestive GVHD, and found that the eosinophil density in the digestive tissue correlated with GVHD severity. Therefore, although not yet confirmed, these authors have concluded that eosinophilia indicates a potential development of GVHD. 7, 8 However, only very few reports are available examining the relationship between eosinophilia after SCT and disease outcome.
In this study, we investigated the frequency of eosinophilia in 113 SCT patients (with both malignant and nonmalignant conditions), retrospectively. We subsequently examined the difference in survival rates between patients with and without eosinophilia. In patients with malignant diseases, we also compared event-free survival and relapse rates between the two groups. To understand the underlying cause of eosinophilia after SCT, selected serum cytokine levels were analyzed both during and after SCT. In conclusion, we propose that eosinophilia after SCT is a useful prognostic marker for determining a favorable outcome in patients with malignant diseases, and may also be useful in patients with nonmalignant diseases.
Patients and methods

Patients
Between February 1988 and February 2005, a total of 160 patients received SCT at Hokkaido University Hospital. Of these patients, 113 were included in this study, while 47 patients were excluded because of insufficient laboratory data, extremely early patient death after SCT (within day þ 70 after transplantation), graft failure, and autologous SCT. The median age of these 113 patients was 8.0 years (range: 0-21), 70 were boys and 43 were girls. Of the patients, 33 had acute lymphoblastic leukemia: 15 were in their first complete remission (CR), 13 in their second CR, and two in their third or higher CR. Three were non-CR. Among the patients, 23 had acute myelogenous leukemia: 12 were in their first CR and 10 in their second CR. One patient was non-CR. A total of 26 patients had other malignant diseases. A total of 31 patients had nonmalignant diseases: 18 had aplastic anemia (AA) and five had Wiskott-Aldrich syndrome. Eight patients had other nonmalignant diseases.
A total of 89 patients received bone marrow transplantation (BMT), one patient underwent peripheral blood stem cell transplantation, and 23 patients received cord blood stem cell transplantation (CBSCT). The transplantation donors were HLA-matched related for 49 patients, mismatched related for nine patients, matched unrelated for 40 patients, and mismatched unrelated for 15 patients.
For conditioning, busulfan (BU)-containing regimens were used in 48 patients, total body irradiation-containing regimens in 60 patients, melphalan-containing regimens in 29 patients, cyclophosphamide (CY)-containing regimens in 76 patients, and anti-lymphocyte globulin-containing regimens in 32 patients. As prophylaxis for GVHD, 61 patients received cyclosporine A (CsA) and short-term methotrexate, two patients received CsA alone, 21 patients received CsA and methyl prednisolone, 22 patients received tacrolimus (FK506) and short-term MTX, six patients received MTX alone, and one patient received FK506 and methyl prednisolone.
Supportive care
Antibacterial and antifungal prophylaxis was administered with oral polymyxin B and amphotericin B. Antiviral prophylaxis was administered with oral acyclovir and intravenous g-globulin. Granulocyte colony-stimulating factor was given intravenously at 5 mg/kg from day þ 5 to engraftment, which was defined as an absolute neutrophil count of 0.5 Â 10 9 /l for 3 consecutive days. Acute GVHD was diagnosed and graded according to the published criteria. 9 Acute GVHD was treated with prednisolone, methylprednisolone, CsA, and/or FK506. Chronic GVHD was assessed using established criteria in those patients who survived until at least day þ 100 after SCT. 10 
Eosinophilia
Peripheral complete blood counts were measured daily on samples taken each morning from every SCT patient until day þ 40 after SCT. Furthermore, the complete blood count was measured twice or three times a week after day þ 40. Microscopic examination of blood smear was performed at least two times. Eosinophilia was defined as an absolute eosinophil count (AEC) of 4500 Â 10 6 /l on at least 2 consecutive days after SCT.
11
Systemic corticosteroid therapy after SCT Of 113 patients included this study, 68 patients (60.2%) received systemic corticosteroid therapy after SCT. Prophylaxis or treatment for acute and/or chronic GVHD was administered with prednisolone (1-2 mg/kg/day) or methyl prednisolone (0.5-1.0 mg/kg/day). The median duration for using corticosteroid was 64 days (range: 6-408).
Assay for serum cytokines
Sera from the patients were collected after obtaining informed consent. Venous blood samples were aseptically collected and centrifuged within 2 h of blood collection and the sera stored at À801C for subsequent analysis. Serum cytokine levels were studied in 26 patients. Out of the 26 patients, 13 were selected from the patients displaying eosinophilia, and the other 13 were selected from patients without eosinophilia. The mean levels of cytokines were evaluated prior to the start of the conditioning treatment regimen (mean: day À7) (pre), soon after transplantation (mean: day þ 37) (early), and at a later time after transplantation (mean: day þ 76) (late). In the eosinophilia patients, we defined blood samples obtained at around the time of the peak AEC as the data derived soon after transplantation (early). Serum cytokine levels were assessed using enzyme-linked immunosorbent assay for IL-1a, IL- 
Statistical analysis
All statistical analyses were carried out using two-tailed tests, 5% levels of significance. For comparison of continuous variables, the Mann-Whitney U-test was used. The association between categorical variables was investigated by a w 2 or Fisher exact probability test. Multivariate analysis stepwise regression was performed to explore the independent effects of variables that showed a significant influence in univariate analysis. Analyses of overall survival and event-free survival were performed using the KaplanMeier method, with differences compared using a log-rank test.
Results
Eosinophilia after SCT
Of the 113 patients, 44 (38.9%) developed eosinophilia after SCT, with the mean time point for maximal AEC occurrence being 67.5 days (range: 23-253 days) after SCT. The mean maximum AEC was 840.5 Â /l for each treatment, respectively. Among the stem cell sources, there was no significant difference between the day on which eosinophilia occurred or the AEC (P ¼ 0.226 and 0.276, respectively).
Of the 44 patients with eosinophilia, 27 (61.4%) were given systemic corticosteroid after SCT. A total of 12 patients were given corticosteroid prior to the time of the peak AEC, 10 were given during the peak AEC, and five were given at a later time after the peak AEC. No significant differences were identified in the presence of eosinophilia and systemic corticosteroid therapy.
A comparison of the profiles between patients with and without eosinophilia after SCT treatment is shown in Table 1 . Only the age of the patient was significantly associated with eosinophilia after SCT. There were no significant correlations between eosinophilia after SCT and the sex of patients, type of disease, difference in the source of donor or of stem cells, and difference in the conditioning regimen, onset of acute/chronic GVHD, and use of prophylactic GVHD immunosuppressant.
Outcome of SCT in patients with and without eosinophilia
In the 113 patients (both with malignant and nonmalignant conditions) who underwent SCT, the overall survival was significantly higher in patients who displayed eosinophilia after SCT compared to those without eosinophilia (88.7 vs 43.0%, P ¼ 0.0034) (Figure 1a) . Similarly, of the 82 patients with a malignant disease, event-free survival was also significantly higher in patients with eosinophilia compared to those without eosinophilia (81.1 vs 44.6%, P ¼ 0.0025) (Figure 1b) . Moreover, of the patients with a malignant disease, a comparison of those who developed eosinophilia after SCT with those without eosinophilia showed a significant difference in cumulative relapse rate (16.0 vs 43.0%, P ¼ 0.0287) (Figure 1c ). Multivariate analysis revealed that eosinophilia after SCT was the only factor, except for the patient's disease subtype, associated with extended survival times ( Table 2 ). In addition, although not statistically significant (to the Po0.05 level) in our sample size, patients with nonmalignant diseases and eosinophilia were prone to have higher overall survival rates compared to those without eosinophilia (100.0 vs 82.4%, P ¼ 0.1093).
As systemic corticosteroid therapy, no significant differences were identified in the overall survival and the eventfree survival in both groups of patients with or without corticosteroid therapy (P ¼ 0.0596 and 0.1047, respectively). Except for relapse, patients with eosinophilia died of chronic GVHD, interstitial pneumonia (IP), and venoocculusive disease (VOD). On the other hand, the causes of death in the patients without eosinophilia were acute/ chronic GVHD, VOD, cerebral hemorrhage, IP, fungal pneumonia, and pulmonary hemorrhage.
Serum cytokine levels in patients with or without eosinophilia after SCT Table 3 summarizes the mean levels of IL-2, IL-4, IL-5, IL-10, IL-12, IFN-g, and TNF-a in the groups with and without eosinophilia after SCT. IL-1a, IL-1b, and IL-8 were below detectable levels. The kinetics of the mean cytokine levels in both groups of patients (13 with and 13 without eosinophilia) are shown in Figure 2 . Of the 13 patients with eosinophilia, nine had malignant disease, acute GVHDXgrade II occurred in two patients (15.4%), and chronic GVHD occurred in five patients (38.5%), while in the 13 patients without eosinophilia, nine also had malignant disease, three patients suffered from acute GVHDXgrade II (23.1%), and chronic GVHD occurred in four patients (30.8%). No significant differences were identified in the types of disease, systemic corticosteroid therapy, and the onset of acute/chronic GVHD in both groups of patients. Only the mean IL-10 and IL-12 levels at the time of the AEC peak after SCT differed significantly between the groups with and without eosinophilia (Po0.05). In the patients without eosinophilia, IL-10 levels peaked at the same time point as that of the peak AEC in patients with eosinophilia. In contrast, peaks in IL-10 levels were not observed in patients with eosinophilia ( Figure 2c ). As shown in Figure 2d , IL-12 level peaks were seen at the same time as that of the AEC peak in patients with eosinophilia. Patients who failed to develop eosinophilia after SCT showed no IL-12 peaks. There was a trend toward higher IL-5 levels in patients with eosinophilia at a time close to the AEC peak when compared to patients without eosinophilia (Figure 2b ). However, this could not be demonstrated as significant using the current data set. IFN-g and TNF-a levels did not differ between the two groups after SCT (Figure 2e and f). (c) Cumulative relapse rates for patients with and without eosinophilia in a population of patients with malignant disease. Patients with eosinophilia after SCT had significantly higher overall survival (88.7 vs 43.0%, P ¼ 0.0034) and event-free survival (81.1 vs 44.6%, P ¼ 0.0025) compared with patients without eosinophilia. Moreover, a comparison of the patients with eosinophilia after SCT with those without eosinophilia revealed a significant difference in the cumulative relapse rate (16.0 vs 43.0%, respectively, P ¼ 0.0287).
Discussion
In this study, we have examined the frequency of patient eosinophilia after SCT and revealed that eosinophilia could be a prognostic marker for favorable patient outcome. This conclusion applies to patients with malignant conditions, but is also very likely for patients with nonmalignant conditions. To study the pathogenesis of eosinophilia after SCT, we analyzed various serum cytokine levels during SCT. Although a few reports have described eosinophilia after allogeneic SCT, this is the first report to show the significance of eosinophilia in disease outcome after SCT.
As shown in Figure 1a , all patients with eosinophilia after SCT showed significantly higher survival rates compared to those without eosinophilia. In particular, patients with malignant conditions who exhibited eosinophilia showed a higher event-free survival ( Figure 1b) and a lower relapse rates than those without eosinophilia (Figure 1c ), suggesting that graft-versus-leukemia (GVL) effects were involved in these results. We were expecting high serum IL-5 levels during SCT in patients with eosinophilia. However, no statistical difference in serum IL-5 was observed between SCT patients with and without eosinophilia, although IL-5 levels at each sampling point were slightly (but not significantly) higher in patients with eosinophilia than those without. Instead, high serum levels of IL-12 and low serum levels of IL-10 were observed in SCT patients with eosinophilia. In promoting GVL effects, IL-12 seems to play an important role. Some authors have in previous reports 12 established an antitumor effect of IL-12 administration. Thus, our results are consistent with this speculation, because SCT patients with eosinophilia had significantly higher serum IL-12 levels than those without eosinophilia. In addition, significantly higher levels of serum IL-10 were observed in SCT patients without eosinophilia in this study (Figure 2c ). Considering the immune suppressive character of IL-10, 13 this result is compatible with the poor prognosis of patients without eosinophilia during SCT. Eosinophilia during SCT might be an indicator of high IL-12/low IL-10 levels; nevertheless, the mechanism underlying these cytokine patterns during eosinophilia remains unknown. In previous studies, some authors demonstrated that combined IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF), which contributes to the production and activation of eosinophils, provided antitumor immunity. 14, 15 In patients with eosinophilia, higher levels of GM-CSF, not investigated in this study, might not only reflect a higher production of IL-12 16 but also the production and activation of eosinophils. To address these hypotheses, however, further studies will be necessary.
SCT-treated patients with nonmalignant diseases who exhibited eosinophilia tend to have higher overall survival rates compared to those without eosinophilia, although this was not statistically confirmed (100.0 vs 82.4%, P ¼ 0.1093). We presume that eosinophilia after SCT is a favorable sign of proper donor cell engraftment. Imoto et al 17 reported no obvious eosinophilia observed in SCT cases, although IL-5 levels increased after SCT treatment. They speculated that the absence of eosinophilia might be due to insufficient bone marrow recovery after SCT and/or deficiency of more factors indispensable for eosinophil recruitment. Our results are supported by their view.
In the previously reports, many authors have pointed out that eosinophilia after SCT is correlated with the development of acute and/or chronic GVHD. Through the statistical analysis, however, the present study clearly shows that eosinophilia after SCT is not directly correlated with clinically apparent GVHD. However, because the occurrence of GVHD is less frequent in childhood than that in adult, our study might not clearly show that eosinophilia after SCT was correlated with GVHD.
No particular preparative regimen such as BU and CY was found to be associated with eosinophilia after SCT in the present study, as some authors suggested. 18 Furthermore, in this study, no relationship between eosinophilia and any immunosuppressant was detected. Only younger patients were significantly associated with eosinophilia (Table 1) as has been previously reported. 19 This observation may be linked to the fact that a better SCT prognosis is predicted for younger patients in some genetically based diseases such as congenital immunodeficiency. 20 In conclusion, we have demonstrated that patients with eosinophilia after SCT treatment show an apparently higher survival rate and event-free survival rates compared to those without eosinophilia after SCT. Therefore, these data lead us to conclude that eosinophilia after SCT might be a favorable outcome prognostic marker for SCT. However, confirmatory results from further prospective studies are needed before eosinophilia can be fully accepted as a prognostic marker for SCT.
